Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Ophthalmology (Rochester, Minn.)

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ophtha.2016.12.025PMID 28341474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey

  2017cited by this paper
• Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey

  2016cited by this paper
• Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone

  2016cited by this paper
• The German ROP Registry: data from 90 infants treated for retinopathy of prematurity

  2016cited by this paper
• Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

  2016cited by this paper
• Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity

  2016cited by this paper
• Current Practice Patterns for Treatment of Retinopathy of Prematurity.

  2016cited by this paper
• Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

  2016cited by this paper
• Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.

  2015cited by this paper
• Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity

  2015cited by this paper
• Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.

  2015cited by this paper
• REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER RANIBIZUMAB TREATMENT

  2015cited by this paper
• Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.

  2015cited by this paper
• Pathophysiology and mechanisms of severe retinopathy of prematurity.

  2015cited by this paper
• Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.

  2015cited by this paper
• INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY: Comparison Between Ranibizumab and Bevacizumab

  2015cited by this paper
• Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.

  2015cited by this paper
• Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey

  2015cited by this paper
• Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab

  2015cited by this paper
• Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity

  2014cited by this paper
• Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

  2014cited by this paper
• Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

  2014cited by this paper
• Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

  2014cited by this paper
• Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010

  2013cited by this paper
• An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.

  2013cited by this paper
• Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

  2013cited by this paper
• Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II

  2012cited by this paper
• Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

  2012cited by this paper
• On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels

  2010cited by this paper
• Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

  2008cited by this paper
• Retinopathy of prematurity

  2007cited by this paper
• IGF-1 and Retinopathy of Prematurity in the Preterm Infant

  2005cited by this paper
• The International Classification of Retinopathy of Prematurity revisited.

  2005cited by this paper
• Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

  2004cited by this paper
• Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial.

  2003cited by this paper
• The Management of Retinopathy of Prematurity

  2001cited by this paper
• Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.

  1996cited by this paper
• Involvement of oxidative stress in D-xylose-induced cataractogenesis in cultured rat lenses.

  1996cited by this paper
• Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

  1995cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

  1988cited by this paper
• Clinical Ophthalmology Dovepress Intraocular and Systemic Levels of Vascular Endothelial Growth Factor in Advanced Cases of Retinopathy of Prematurity

  year unknowncited by this paper

• ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy

  2026cites this paper
• The Role of Anti-vascular Endothelial Growth Factor (anti-VEGF) in Retinopathy of Prematurity (ROP)

  2025cites this paper
• Microglial HMOX1 drives retinal angiogenesis via modulation of endothelial STAT3 signaling.

  2025cites this paper
• Geographic and socioeconomic disparities to retinopathy of prematurity treatment

  2025cites this paper
• Laser Photocoagulation Subsequent to Intravitreal Ranibizumab for Retinopathy of Prematurity Long-Term Efficacy in Extremely Low Birth Weight Twins

  2025cites this paper
• From Screening to Therapy: A Personalized Approach to ROP in a National NICU Setting

  2025cites this paper
• Repeat Intravitreal Bevacizumab in a Very Low Birth Weight Infant with Recurrent ROP: 3-Year Follow-Up and Literature Review

  2025cites this paper
• BARD1-mediated stabilization of METTL14 promotes retinal neovascularization by m6A-modifying MXD1 mRNA on a YTHDF2-dependent manner

  2025cites this paper
• Species composition and antibiotic resistance of the conjunctival microflora of premature newborns during natural delivery

  2025cites this paper
• A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.

  2025cites this paper
• Identification of genetic factors underlying severe retinopathy of prematurity in preterm infants

  2025cites this paper
• Retinal Blood Vessel Formation in the Macula Following Intravitreal Ranibizumab Injection for Aggressive Retinopathy of Prematurity

  2024cites this paper
• Outcomes and Need for Additional Interventions Following Intravitreal Bevacizumab for Retinopathy of Prematurity.

  2024cites this paper
• Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies

  2024cites this paper
• Autophagy‐mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization

  2024cites this paper
• Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy

  2024cites this paper
• Icariin alleviates oxygen‐induced retinopathy by targeting microglia hexokinase 2

  2024cites this paper
• Long-term outcomes of visual motor integration and motor development children with retinopathy of prematurity

  2024cites this paper
• LONGITUDINAL CHANGES IN CHOROIDAL THICKNESS IN CHILDREN WITH A HISTORY OF PREMATURITY

  2024cites this paper
• Retinopathy of Prematurity—Targeting Hypoxic and Redox Signaling Pathways

  2024cites this paper
• Intra-Anterior Chamber Injection of Ranibizumab in Advanced Pediatric Vitreoretinal Diseases.

  2024cites this paper
• Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)

  2024cites this paper
• Conbercept versus laser for the treatment of infants with Zone II retinopathy of prematurity.

  2024cites this paper
• Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography

  2023cites this paper
• An Artificial Intelligence System for Screening and Recommending the Treatment Modalities for Retinopathy of Prematurity

  2023cites this paper
• Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration

  2023cites this paper
• Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials

  2023cites this paper
• An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

  2023cites this paper
• Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries

  2023cites this paper
• Pulmonary Hypertension and Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity-Is There a Link?

  2022cites this paper
• Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.

  2022cites this paper
• Effect of ranibizumab on retinopathy of prematurity: A meta-analysis

  2022cites this paper
• The cerebrospinal fluid proteome of preterm infants predicts neurodevelopmental outcome

  2022cites this paper
• A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity.

  2022cites this paper
• The Determinative Role of Cytokines in Retinopathy of Prematurity.

  2022cites this paper
• NADH-Cytochrome B5 reductase 2 suppresses retinal vascular dysfunction through regulation of vascular endothelial growth factor A in diabetic retinopathy.

  2022cites this paper
• Intravitreal Bevacizumab is Associated with Prolonged Ventilatory Support in Preterm Infants with Bronchopulmonary Dysplasia.

  2022cites this paper
• Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

  2022cites this paper
• National guideline for ophthalmological screening of premature infants in Germany (S2k level, AWMF guidelines register no. 024/010, March 2020)

  2022cites this paper
• Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis

  2022cites this paper
• Retinopathy of prematurity

  2022cites this paper
• Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab

  2022cites this paper
• One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity

  2022cites this paper
• Efficacy comparison of 21 interventions to prevent retinopathy of prematurity: a Bayesian network meta-analysis of randomized controlled trials

  2022cites this paper
• Late sequelae of retinopathy of prematurity in adolescence and adulthood

  2022cites this paper
• Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity

  2021cites this paper
• Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again

  2021cites this paper
• The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity

  2021cites this paper
• Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis

  2021cites this paper
• Management of retinopathy of prematurity (ROP) in a Polish cohort of infants

  2021cites this paper
• Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial

  2021cites this paper
• Neurodevelopmental Outcomes in Preterm Infants with Retinopathy of Prematurity.

  2021cites this paper
• Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)

  2021cites this paper
• MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity.

  2021cites this paper
• Oxygen management among infants in neonatal units in sub-Saharan Africa: a cross-sectional survey

  2021cites this paper
• Blindness Secondary to Retinopathy of Prematurity in Sub-Saharan Africa

  2021cites this paper
• Neurodevelopmental Outcomes Associated With Intravitreal Bevacizumab Injections for Retinopathy of Prematurity

  2021cites this paper
• Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.

  2021cites this paper
• Ten-year outcomes after initial management with laser photocoagulation versus intravitreal bevacizumab injection in a pair of identical twins with aggressive posterior retinopathy of prematurity

  2021cites this paper
• Investigating the factors affecting myopia in retinopathy of prematurity after laser treatment

  2021cites this paper
• Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity

  2021cites this paper
• Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity

  2021cites this paper
• Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society

  2021cites this paper
• Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity

  2021cites this paper
• Macular Hole as a Complication Following Laser Photocoagulation for Retinopathy of Prematurity.

  2021cites this paper
• Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).

  2021cites this paper
• The Clinical Use of Ultra - Wide Field Imaging and Intravenous Fluorescein Angiography in Infants with Retinopathy of Prematurity.

  2021cites this paper
• Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions

  2020cites this paper
• Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity

  2020cites this paper
• Neurodevelopmental Outcomes After Bevacizumab Treatment for Retinopathy of Prematurity-A Meta-Analysis.

  2020cites this paper
• Flying baby optical coherence tomography alters the staging and management of advanced retinopathy of prematurity

  2020cites this paper
• Outcomes of Nonconfluent Diode Laser Panretinal Photocoagulation for Aggressive Posterior Retinopathy of Prematurity After Intravitreal Bevacizumab.

  2020cites this paper
• Comparison of foveal thickness in preschool children with a history of retinopathy of prematurity and laser photocoagulation or anti-vascular endothelial growth factor treatment: a prospective, longitudinal study

  2020cites this paper
• Acetylcholinesterase inhibition ameliorates retinal neovascularization and glial activation in oxygen-induced retinopathy.

  2020cites this paper
• Current management of retinopathy of prematurity in sub-Saharan Africa.

  2020cites this paper
• Ferrochelatase regulates retinal neovascularization

  2020cites this paper
• Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity.

  2020cites this paper
• ASK1-Mediated Phosphorylation Blocks HDAC6 Ubiquitination and Degradation to Drive the Disassembly of Photoreceptor Connecting Cilia.

  2020cites this paper
• Inadequate laser coagulation is an important cause of treatment failure in Type 1 retinopathy of prematurity

  2020cites this paper
• Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis.

  2020cites this paper
• Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity

  2020cites this paper
• Screening and novel therapies for retinopathy of prematurity - A review.

  2019cites this paper
• Agresif Posterior Prematüre Retinopatisinde İntravitreal Bevacizumab Monoterapisinin Uzun Dönem Etkinliğinin Değerlendirilmesi Long-Term Efficacy of Intravitreal Bevacizumab Monotherapy in Aggressive Posterior Premature Retinopathy

  2019cites this paper
• EB_A_189684 25..35

  2019cites this paper
• Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity

  2019cites this paper
• RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.

  2019cites this paper
• Fluoreszenzangiografieassistiertes Management von Rezidiven bei aggressiver posteriorer Frühgeborenenretinopathie (APROP) nach intravitrealer Monotherapie mit 0,312 mg Bevacizumab

  2019cites this paper
• TEN-YEAR EPIDEMIOLOGY OF RETINOPATHY OF PREMATURITY TREATMENT IN TAIWAN.

  2019cites this paper
• A Dosing Study of Bevacizumab for ROP: Late Recurrences and Additional Treatments

  2019cites this paper
• Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.

  2019cites this paper
• Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

  2019cites this paper
• Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation

  2019cites this paper
• Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser

  2019cites this paper
• SEVERE RECURRENT FIBROVASCULAR PROLIFERATION AFTER COMBINED INTRAVITREAL BEVACIZUMAB INJECTION AND LASER PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY

  2019cites this paper
• Plasma VEGF Concentrations after Intravitreous Anti-VEGF Therapy for Diabetic Macular Edema

  2019cites this paper
• A Quantitative Severity Scale for Retinopathy of Prematurity Using Deep Learning to Monitor Disease Regression After Treatment.

  2019cites this paper
• Retinopathy of prematurity associated with oculocutaneous albinism: Laser treatment is not an option.

  2019cites this paper
• Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

  2019cites this paper
• Successful treatment of aggressive posterior retinopathy of prematurity with diode laser in ocular albinism: A case report

  2019cites this paper
• EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS

  2019cites this paper